Associat Director, Corporate Strategy at Abata Therapeutics

Burlington, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

BiotechnologyIndustries

Requirements

Bachelor’s degree in Finance, Accounting, Economics, or related field; Master’s degree preferred
8+ years of progressive experience in FP&A, strategic finance, or corporate planning
Demonstrated ability to build dynamic financial models and conduct scenario planning to support pipeline valuation and investment decisions
Strong understanding of the biotech development and commercialization lifecycle, including key drivers such as pricing, market access, and program cost structures
Experience translating scientific and market insights into strategic financial implications; exposure to competitive intelligence or portfolio planning is a plus
Proficiency in financial systems (e.g., NetSuite, Adaptive Insights, Anaplan, Tableau, Excel)
Excellent communication and interpersonal skills, with the ability to partner cross-functionally and influence stakeholders at all levels
Comfortable operating in a fast-paced, pre-commercial or high-growth biotech environment with evolving processes
Highly organized, analytical, and capable of managing multiple priorities independently
Hybrid role on-site 3 days per week in Redwood City, CA or Burlington, MA
Ability to travel as needed (up to 20%) for corporate and department-wide meetings

Responsibilities

Act as a strategic finance partner to Clinical Development, Medical Affairs, and other commercial and corporate functions, supporting integrated planning, resource allocation, and cross-functional alignment
Provide financial insights for program reviews, portfolio prioritization, business development opportunities, and other strategic decision-making discussions
Support clinical and commercial planning through primary and secondary research
Integrate competitive intelligence and market analytics into financial modeling by translating external landscape insights into actionable planning assumptions
Develop long-range planning models, program-level forecasts, and valuation frameworks to assess pipeline potential, launch readiness, and other investment decisions
Support resource planning in partnership with functional leaders to support program execution and organizational scaling
Create dashboards and data visualizations to track KPIs, development progress, and resource utilization
Assist with board presentations, investor materials, and other executive communications
Contribute to the optimization of finance systems and tools (e.g., NetSuite, Adaptive Insights, Coupa) to enhance planning accuracy, efficiency, and scalability
Help establish the financial infrastructure, tools, and processes needed to support MapLight’s growth

Skills

Financial Modeling

NetSuite

Adaptive Insights

Coupa

Data Visualization

Competitive Intelligence

Market Analytics

Forecasting

Valuation Frameworks

Resource Planning

Board Presentations

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free